Steroid-Refractory Acute GVHD: Predictors and Outcomes

Table 2

Evaluation of predicators of first-line therapy for treatment of acute GVHD.

Predictor	No. of patients	CR/PR, no. of patients	OR	Univariate 95% CI	𝑃
Grade at first line therapy
I	89	58 (65)	Reference	—	—
II	141	81 (57)	0.7	0.4–1.2	0.2
III	54	21 (39)	0.3	0.2–0.7	0.003
IV	3	1 (33)	0.3	0.02–3.1	0.3
Grade III-IV			0.4	0.2–0.7	0.003
Age
≤45 (median)	138	74 (54)	Reference	—	—
>45	149	87 (58)	1.2	0.8–1.9	0.4
Gender
F	112	60 (54)	0.8	0.5–1.4	0.5
M	175	101 (58)	Reference	—	—
Donor/patient sex
Female/Male	73	37 (51)	0.7	0.4–1.3	0.3
Other	214	124 (58)	Reference	—	—
Conditioning regimen
Total body irradiation	48	27 (56)	1.1	0.5–2.2	0.8
High Dose, No total body irradiation	137	90 (57)	1.1	0.6–1.9	0.7
Reduced intensity	102	44 (54)	Reference
Allotype
Matched	251	146 (58)	1.9	0.96–3.9	0.06
Mismatched	36	15 (42)	Reference	—	—
Cell type
BM	161	87 (54)	0.8	0.5–1.3	0.4
PB	126	74 (59)	Reference	—	—
Diagnosis
Myeloid	163	90 (55)	0.6	0.2–2.0	0.4
Lymphoid	100	59 (59)	Reference	—	—
Multiple myeloma	8	3 (37)	Excluded	—	—
Other	4	4 (100)	Excluded	—	—
Solid	12	5 (42)	Excluded	—	—
Disease status at transplant
Active disease	188	113 (60)	1.6	0.98–2.6	0.06
No active disease	99	48 (48)	Reference	—	—
Prior chemotherapy regimens
≤2	182	100 (55)	Reference	—	—
>2	105	61 (58)	1.1	0.7–1.8	0.6
Dose of methylprednisolone first line
<2 mg	24	15 (62)	Reference	—	—
2 mg	250	144 (58)	0.8	0.3–1.9	0.6
Unknown	13	2 (15)	Excluded
Days from transplant to aGVHD
≤14	73	31 (42)	Reference	—	—
>14	214	130 (61)	0.5	0.3–0.8	0.007
CD34 infused (quartile)
≤3.5	72	40 (56)	Reference	—	—
>3.5 to ≤4.3	68	42 (62)	1.3	0.7–2.5	0.5
>4.3 to ≤5.5	73	40 (55)	0.97	0.5–1.9	0.9
>5.5	70	37 (37)	0.9	0.5–1.7	0.7